Skip Navigation LinksHome > December 2013 - Volume 24 - Issue 6 > Niacin: a long history, but a questionable future
Current Opinion in Lipidology:
doi: 10.1097/MOL.0000000000000017
THERAPY AND CLINICAL TRIALS: Edited by Anton F. Stalenhoef and John J.P. Kastelein

Niacin: a long history, but a questionable future

Ginsberg, Henry N.; Reyes-Soffer, Gissette

Collapse Box

Abstract

Purpose of review

To provide an update on recent mechanistic and clinical trial data related to the actions and efficacy of niacin.

Recent findings

Recent mechanistic studies have provided novel insights regarding the mechanism of action of niacin. Studies of the purported niacin receptor, GPR109A, indicate that niacin-mediated fatty acid-lowering and flushing are dependent on niacin binding to this receptor, whereas the lipid-altering effects of niacin may be independent of the interaction of niacin with the receptor. Two cardiovascular outcome trials – Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health trial and HPS2-THRIVE – were both negative.

Summary

Niacin has been used to treat dyslipidemia for almost 60 years. Recent studies have provided clues to niacin's broad lipid-altering efficacy, but more work is required to fully understand its mechanisms of action. The failure of niacin to reduce cardiovascular events in two recent placebo-controlled trials of high-risk patients with LDL-cholesterol levels less than 70 mg/dl on statins was surprising based on prior outcome and surrogate studies. We await publication of subgroup analyses to allow full assessment of those trials. In the meantime, we should not forget that niacin is an effective LDL-cholesterol-lowering drug in patients with high LDL levels despite statin treatment.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.